Doctor's Guide -- CHICAGO -- October 10, 2010 -- A new ultra-low formulation of oestriol satisfied nearly three-fourths of the women who received it, improving symptoms associated with vaginal atrophy. The findings were presented here at the 21st Annual Meeting of the North American Menopause Society (NAMS).
